Cerezyme market set for growth as rare disease treatment demand rises
The Business Research Company says the global Cerezyme market is poised for steady expansion through 2030, driven by higher Gaucher disease diagnosis rates, rising healthcare spending and broader access to enzyme replacement therapy. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.
Why it matters: - Cerezyme is a specialized enzyme replacement therapy used to treat Gaucher disease, a rare genetic disorder with limited treatment options. - Market growth could improve access to long-term care for patients with rare lysosomal storage disorders. - Expansion in reimbursement, biologic manufacturing and home infusion care could make treatment easier to deliver.
What happened: - The Business Research Company published its Cerezyme Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Cerezyme market is gaining attention as rare disease treatment advances and healthcare infrastructure improves. - A free sample of the report is available here. - The full report is available here.
The details: - Cerezyme replenishes the missing glucocerebrosidase enzyme in Gaucher disease. - The therapy helps manage spleen and liver enlargement, anemia, low platelet counts and bone problems. - It reduces fatty substance buildup in affected organs and tissues. - The market’s past growth was supported by scarce treatment options, improved diagnostics for rare diseases, early use in specialty clinics and orphan-drug incentives. - Future growth is expected to come from greater awareness of lysosomal storage disorders, broader reimbursement coverage, advances in biologic manufacturing, growth in home-based infusion care and continued orphan-drug benefits. - Key trends include sustained reliance on enzyme replacement therapies, rising diagnosis rates for rare genetic disorders, longer-term disease management and broader access to treatment for rare conditions. - The report says increasing research and development spending is a major growth driver. - The report also points to healthcare infrastructure expansion as another driver. - The market analysis includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.
Between the lines: - The report frames Cerezyme demand as part of a broader shift toward chronic management of rare diseases rather than one-time treatment. - Rising healthcare spending and stronger infrastructure matter because enzyme replacement therapy depends on diagnosis, specialty care and ongoing administration. - The regional split suggests mature markets will remain revenue anchors while faster growth may come from regions still building rare-disease treatment capacity. - The report cites the G-FINDER 2024 report, which showed global hepatitis C research funding rose by $5 million, or 30%, in 2023 to $21 million. - The American Medical Association reported U.S. health spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person.
What’s next: - Broader diagnosis of Gaucher disease and other rare genetic disorders could expand the treated patient pool. - Continued reimbursement gains and home-infusion adoption may improve treatment access. - The report expects Asia-Pacific to outpace other regions as healthcare systems and rare-disease awareness improve. - Further gains will likely depend on sustained R&D investment and biologic manufacturing progress.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Asia Pacific Examiner
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.